体外模型在药物性肝损伤的应用进展

被引：13

作者：

吴宇 ^{[1
,2
]}

耿兴超 ^{[2
]}

汪巨峰 ^{[2
]}

李波 ^{[1
,3
]}

机构：

[1] 中国医学科学院北京协和医学院

[2] 中国食品药品检定研究院国家药物安全评价监测中心药物非临床安全评价研究北京市重点实验室

[3] 中国食品药品检定研究院

来源：

中国新药杂志 | 2015年 / 22期

关键词：

药物性肝损伤; 体外模型; 单层培养; 共培养; 3D培养; 虚拟筛选;

D O I：

暂无

中图分类号：

R575 [肝及胆疾病];

学科分类号：

100201 [内科学];

摘要：

药物性肝损伤(drug-induced liver injury,DILI)是新药研发上市后被撤市或限制使用的主要原因。由于临床表现复杂,发病率低,而且涉及化学药、中草药和膳食补充剂等种类繁多,在临床前药物筛选过程中难以有效发现药物对肝的损伤作用。国内外均在探索和研究能够预测DILI的相关体外模型,本文汇总了当前国内外DILI最新体外模型研究进展,以期为致肝损伤药物早期筛选和评价模型的合理选择提供参考。

引用

页码：2548 / 2554

页数：7

共 25 条

[1]

体外连续培养的成人肝细胞的超显微结构 [J].

叶秀珍 ;

朱德厚 ;

沈鼎武 .

实验生物学报, 1980, (04) :361-369

[2]

Idiosyncratic Drug Hepatotoxicity: Strategy for Prevention and Proposed Mechanism[J] Toshihiko Ikeda Current Medicinal Chemistry 2015,

[3]

Biokinetics of chlorpromazine in primary rat and human hepatocytes and human HepaRG cells after repeated exposure[J] Jessica J.W. Broeders;Céline Parmentier;Germaine L. Truisi;Rozenn Jossé;Eliane Alexandre;Camille C. Savary;Philip G. Hewitt;Stefan O. Mueller;André Guillouzo;Lysiane Richert;Jan C.H. van Eijkeren;Joop L.M. Hermens;Bas J. Blaauboer Toxicology in Vitro 2015,

[4]

How useful are clinical liver function tests in in vitro human hepatotoxicity assays?[J] Jürgen Borlak;Anil Chougule;Prafull Kumar Singh Toxicology in Vitro 2014,

[5]

Toward predictive models for drug-induced liver injury in humans: are we there yet?[J] Minjun Chen;Halil Bisgin;Lillian Tong;Huixiao Hong;Hong Fang;Jürgen Borlak;Weida Tong Biomarkers Med. 2014,

[6]

Evaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicity[J] Dennie GA Hebels;Marlon JA Jetten;Hugo JW Aerts;Ralf Herwig;Daniël HJ Theunissen;Stan Gaj;Joost H van Delft;Jos CS Kleinjans Biomarkers Med. 2014,

[7]

3D Hepatic In Vitro Models as Tools for Toxicity Studies[J] Daniel Mueller;Elmar Heinzle;Fozia Noor Current Tissue Engineering 2013,

[8]

Stem cell‐derived hepatocytes as a predictive model for drug‐induced liver injury: are we there yet?[J] Richard Kia;Rowena L. C. Sison;James Heslop;Neil R. Kitteringham;Neil Hanley;John S. Mills;B. Kevin Park;Chris E. P. Goldring Br J Clin Pharmacol 2013,

[9]

Real-time in situ viability assessment in a 3D bioreactor with liver cells using resazurin assay[J] Daniel Mueller;Georg Tascher;Georg Damm;Andreas K. Nüssler;Elmar Heinzle;Fozia Noor Cytotechnology 2013,

[10]

Optimization of the HepaRG cell model for drug metabolism and toxicity studies[J] Sébastien Anthérieu;Christophe Chesné;Ruoya Li;Christiane Guguen-Guillouzo;André Guillouzo Toxicology in Vitro 2012,

← 1 2 3 →